The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMP.L Regulatory News (AMP)

  • There is currently no data for AMP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Dealings

27 Feb 2009 16:46

RNS Number : 0691O
Amphion Innovations PLC
27 February 2009
 



Amphion Innovations Director Dealings

Distribution to Board Members 

London and New York, 27 February 2009 - Amphion Innovations plc (LSE: AMP), the developer of medical and technology businesses, announces today that Board Members Richard Mansell-Jones, R. James Macaleer, Anthony Henfrey, Robert Bertoldi, and Richard Morgan have received Amphion Innovations plc ordinary shares of 1p in a final distribution of shares made by Amphion Capital Partners LLC ('ACP') as a result of an agreement between ACP and Amphion Innovations dated 16 August 2005 and as detailed in the admission document.  ACP's operations and investment portfolio were acquired by Amphion Innovations following its IPO in August 2005, in return for shares of Amphion Innovations Certain Board Members of Amphion Innovations are shareholders of ACP and received these shares as part of a distribution to all ACP shareholders of 8,025,000 shares. After this distribution, ACP's shareholding in Amphion Innovations has been reduced to zero.

Richard Mansell-Jones, Chairman of Amphion, received 162,814 ordinary shares, bringing his total holdings of the Company to 2,856,588 representing 2.191% of the Company's issued ordinary share capital. 

R. James Macaleer received 2,391,865 ordinary shares, bringing his total beneficiary holding of the Company to 22,308,919 representing 17.111% of the Company's issued ordinary share capital. 

Anthony Henfrey received 106,124 ordinary shares, bringing his total holding of the Company to 1,010,476 representing 0.775% of the Company's issued ordinary share capital. 

Robert Bertoldi, President and Chief Financial Officer of Amphion, received 685,722 ordinary shares, bringing his total holding of the Company to 6,360,566 representing 4.879% of the Company's issued ordinary share capital.

Richard Morgan, Chief Executive Officer of Amphion, received 1,095,846 ordinary shares. Accordingly Richard Morgan is now beneficially interested in 22,794,057 ordinary shares representing 17.483% of the Company's issued ordinary share capital.

For further information please contact 

Amphion Innovations plc  Charlie Morgan, Director of Communications  +1 (212) 210 6224

Cardew Group Tim Robertson/ Jamie Milton/ Matthew Law +44 20 7930 0777

Charles Stanley (Nominated Adviser) Mark Taylor/ Freddy Crossley +44 20 7149 6000

About Amphion Innovations plc

Amphion (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 8 Partner Companies, developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million.

On the web: www.amphionplc.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSBLGDDSSDGGCR
Date   Source Headline
22nd Dec 20177:01 amRNSComment on Polarean Fund Raise
22nd Dec 20177:00 amRNSRestructure of Loan and Additional Drawdown
5th Dec 20177:00 amRNSIssue of Shares
23rd Nov 20177:00 amRNSFurther Update on Polarean Imaging Limited
10th Nov 20177:00 amRNSUpdate on Polarean Imaging Limited
2nd Nov 20177:00 amRNSOrder Dismissing DataTern Case
11th Oct 20177:00 amRNSRelated Party Transaction
5th Oct 20177:00 amRNSPartner Company releases positive clinical results
29th Sep 20177:00 amRNSHalf-year Report
25th Sep 20177:01 amRNSHolding(s) in Company
25th Sep 20177:00 amRNSSale of Partner Company Shares
30th Aug 20177:00 amRNSSale of partner company shares
30th Aug 20177:00 amRNSHolding(s) in Company
1st Aug 20175:19 pmRNSAGM Statement
28th Jun 20177:00 amRNSFinal Results
31st May 20177:00 amRNSPartner Company m2m Imaging merger update
22nd May 20174:36 pmRNSAdditional Draw Down on Loan Facility
7th Feb 20177:00 amRNSAdditional Draw Down on Loan Facility
1st Feb 20175:18 pmRNSHolding(s) in Company
30th Dec 20162:38 pmRNSHolding(s) in Company
16th Dec 20163:07 pmRNSDirector/PDMR Shareholding
9th Dec 20163:50 pmRNSDirector/PDMR Shareholding
24th Nov 20162:15 pmRNSHolding(s) in Company
8th Sep 20167:00 amRNSRe-negotiated terms of Motif CPN
7th Sep 20167:00 amRNSInterim Results for the six months to 30 June 2016
22nd Aug 20163:58 pmRNSAdditional Draw Down on Loan Facility
3rd Aug 20164:13 pmRNSHolding(s) in Company
29th Jul 20167:00 amRNSResults of AGM and Directorate Change
18th Jul 20164:33 pmRNSTransfer of Shares
13th Jul 20167:01 amRNSNotice of Intention to List on NASDAQ by Motif Bio
13th Jul 20167:00 amRNSAdditional Draw Down on Loan Facility
23rd Jun 20167:00 amRNSFinal Results
29th Apr 20164:02 pmRNSAdditional Terms on Loan Facility
28th Apr 20167:00 amRNSAdditional Draw Down on Loan Facility
7th Apr 20167:00 amRNSAmphion settles contested arbitration ruling
3rd Mar 20167:00 amRNSConvertible Promissory Note Extended
7th Jan 20167:00 amRNSDirectors' Dealings
5th Jan 20167:00 amRNSConvertible Promissory Note Terms Extended
26th Nov 20157:00 amRNSAdditional Draw on Loan Facility
5th Nov 20157:00 amRNSPartner Company m2m Imaging Corp. to merge
30th Oct 20154:20 pmRNSDeath of a Director - Replacement
30th Oct 20153:50 pmRNSDeath of a Director
17th Sep 20157:00 amRNSAmphion to present in London
16th Sep 20157:00 amRNSDirectors' Dealings
10th Sep 20157:00 amRNSDataTern Receives Favourable Ruling
3rd Sep 20157:00 amRNSInterim Results
28th Aug 20159:08 amRNSHolding(s) in Company
7th Aug 20155:15 pmRNSResult of AGM
22nd Jul 20154:32 pmRNSFDA QIDP Designation
22nd Jul 20157:00 amRNSFinal condition of £22m placing satisfied

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.